What LifeStance Health Group (LFST) Said on Its Q3 Earnings Call

Key Points

• Strong Q3 results led to a higher outlook: Revenue rose 25% to $456 million, adjusted EBITDA increased 70% to $68 million, and LifeStance raised its 2026 revenue and adjusted EBITDA guidance.
• The EHR transition may slow 2027 growth: Management expects the phased rollout to reduce revenue growth by about 1–2 percentage points, while forecasting continued margin expansion.
• Specialty services and expansion remain growth drivers: LifeStance added TMS and SPRAVATO locations, expects about $70 million in specialty-services revenue this year, and expanded into Iowa, bringing its presence to 34 states.

LifeStance Health Group NASDAQ: LFST raised its full-year 2026 outlook after reporting 25% third-quarter revenue growth, driven by more patient visits and higher revenue per visit. The mental health care provider also said its planned electronic health record transition could temper revenue growth in 2027.

Revenue rose to $456 million in the quarter, while adjusted EBITDA increased 70% to $68 million, producing a 15% margin for the second consecutive quarter. Net income was $22 million, an improvement of $21 million from the year-earlier period.

Chief Financial Officer Ryan McGroarty said both visit volumes and revenue per visit exceeded the company’s expectations. Visits increased 17% to 2.7 million, while total revenue per visit rose 7% to $170, primarily because of payer rate increases.

Clinician Growth and Profitability

LifeStance added a net 321 clinicians during the quarter, bringing its total to 8,863, up 11% from a year earlier. Visits per average clinician increased 5%, which McGroarty attributed in part to gains in early patient engagement.

CEO Dave Bourdon said strong recruiting and stable retention drove the clinician gains. He said retention had improved among the company’s highest-producing clinicians, while newer clinicians remained the group with the lowest retention. LifeStance believes it can improve overall clinician retention by more than 5% over the long run, he added.

Center Margin increased 38% to $161 million, or 35.4% of revenue. Free cash flow rose to $22 million from $17 million a year earlier. McGroarty said the timing of payroll and an annual 401(k) contribution affected third-quarter cash flow, which can be uneven from period to period.

The company ended the quarter with $219 million in cash after repurchasing $25 million of shares during the period. It reported net long-term debt of $256 million.

Full-Year Outlook Raised

LifeStance raised the midpoint of its annual revenue guidance by $46 million and its adjusted EBITDA midpoint by $21 million. Its updated ranges are:

• Revenue: $1.741 billion to $1.761 billion.
• Center Margin: $599 million to $613 million.
• Adjusted EBITDA: $242 million to $250 million.

The revenue midpoint implies 23% annual growth, while the adjusted EBITDA midpoint implies a margin of about 14%, or roughly 3 percentage points of expansion from the prior year, McGroarty said.

For the fourth quarter, LifeStance forecast revenue of $446 million to $466 million and adjusted EBITDA of $56 million to $64 million. Asked about the expected sequential decline in adjusted EBITDA, McGroarty pointed to investments in patient acquisition, technology, clinical excellence, compensation and benefits, as well as planned improvements to some centers.

Electronic Health Record Transition

LifeStance expects implementation of a new electronic health record system to reduce 2027 revenue growth by approximately 1 to 2 percentage points. As a result, the company expects growth toward the lower end of its long-term mid-teens range next year, although management expects margins to continue expanding.

Bourdon said LifeStance plans to begin the phased rollout in one state with a couple hundred clinicians before expanding it across the company during 2027. McGroarty said implementation is expected to be completed by year-end, with no implementation timeline carrying over into 2028.

McGroarty reiterated that the transition is expected to cost roughly $20 million to $30 million, which would be either adjusted out of EBITDA or capitalized. He said the company expects to provide more detail alongside its fourth-quarter results and 2027 guidance.

Specialty Services and Expansion

LifeStance added transcranial magnetic stimulation, or TMS, at five sites and SPRAVATO at four during the quarter. It now offers TMS at 37 centers and SPRAVATO at 25. Both treatments are used for patients with treatment-resistant depression.

Bourdon said recently published company outcomes data showed that 74% of SPRAVATO patients experienced a clinically meaningful reduction in depression severity after 12 weeks. For TMS, the figure was 61% among patients who completed at least 30 sessions. He said the data could support discussions with payers about coverage and reimbursement.

The company remains on track for roughly $70 million in specialty-services revenue this year, up from about $50 million in 2025, Bourdon said. He expects specialty growth next year to be similar to this year’s rate and meaningfully above growth for the overall business.

LifeStance also entered Iowa through a tuck-in acquisition, bringing its presence to 34 states, and opened eight new centers in the quarter. Bourdon said the company expects to continue completing roughly one or two tuck-in acquisitions per quarter and described this year’s target of 20 to 30 new centers as an approximation for 2027.

About LifeStance Health Group (NASDAQ:LFST)

LifeStance Health Group, Inc is a provider of outpatient behavioral health services in the United States. Through a network of clinicians and care centers, the company offers mental health care through in-person appointments and telehealth visits.

LifeStance's services include individual, couples and family therapy; psychiatric evaluation and medication management; psychological and neuropsychological testing; and treatment for conditions such as depression, anxiety, attention-deficit/hyperactivity disorder, bipolar disorder, post-traumatic stress disorder and other behavioral health concerns.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.